Abstract: An orally administered analgesic product comprises 250-1,000 mg of myfadol and a carrier for the myfadol. The orally administered product may be a solid or a liquid. The analgesic effect of the product lasts for 2 to 4 hours or more. The product contains more than 4 mg of myfadol per kg of body weight of the human patient to whom the product is administered. The solid product may contain a delayed release agent that extends the analgesic effect of the myfadol to a total time of up to 12 hours.

Abstract: A composition, for producing pain relief in a body region, comprises a sterile, stable suspension of butyl aminobenzoate in a non-toxic, aqueous carrying medium in which the butyl aminobenzoate is substantially insoluble. The aqueous carrying medium consists essentially of water as the major constituent and a suspending agent composed of (a) polyethylene glycol and (b) a wetting agent for the butyl aminobenzoate, with a ratio of (a) to (b) in the range of about 50/1 to 125/1. The butyl aminobenzoate is milled to a particle size in the range of about 5 to 50 microns in the presence of the suspending agent.

Abstract: A composition and method for producing lasting pain relief in a body by injection. The composition consists essentially of a sterile, stable suspension of butyl aminobenzoate in a non-toxic, aqueous carrying medium in which the butyl aminobenzoate is insoluble. The composition is substantially devoid of dextran and contains polyethylene glycol as a suspending agent.